title: A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin.
abstract: At present, approximately 20% of Hodgkin lymphomas (HL) are relapsed and refractory, and therapeutic methods including chemotherapy, radiotherapy, and even stem cell transplantation are unsatisfactory. Brentuximab vedotin, composed of CD30 antibody and a chemotherapeutic agent, is a new targeted drug that eradicates tumor cells by binding to the CD30 antigen on their surface. In clinical trials, the response rate and complete remission rate of this drug were 73% and 40%, respectively, for relapsed and refractory HL. Here we report a case of CD30-positive relapsed and refractory HL that was treated with brentuximab. Before the treatment with brentuximab, the patient underwent chemotherapy, radiotherapy, and autologous stem cell transplantation. However, the disease continued to progress, affecting multiple organs and prompting symptoms such as persistent fever. After the treatment with brentuximab, the patient's condition improved. Body temperature returned to normal after 4 days. Lung nodules were reduced in size and number after a single course of treatment, and PET/CT showed partial remission and complete remission after 3 and 6 courses of treatment, respectively. The entire treatment process progressed smoothly, though the patient experienced some symptoms due to chemotherapy, including peripheral neuritis of the limbs, irritating dry cough, and mild increase in aminotransferase. No serious adverse effects were observed. The current general condition of the patient is good; the continuous complete remission has amounted to 6 months.
authors.affiliation: Department of Hematology and Oncology, the First Affiliated Hospital of the People's Liberation Army General Hospital, Beijing 100048, P. R. China. Yangqm@medmail.com.cn.
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: Cao
authors.forename: Hong-Wei
authors.initials: HW
authors.lastname: Zhou
authors.forename: Chao-Jin
authors.initials: CJ
authors.lastname: Peng
authors.forename: Mo
authors.initials: M
authors.lastname: Liu
authors.forename: Yu
authors.initials: Y
authors.lastname: Du
authors.forename: Qing-Ming
authors.initials: QM
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D005260:Female; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000378:metabolism; D009364:Neoplasm Recurrence, Local; D051757:PAX5 Transcription Factor / Q000378:metabolism; D049268:Positron-Emission Tomography; D033581:Stem Cell Transplantation; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D051757:PAX5 Transcription Factor; C497281:PAX5 protein, human; D000079963:Brentuximab Vedotin
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9208-18
references.pmid: 16314615
references.citation: J Clin Oncol. 2008 Jan 20;26(3):455-62
references.pmid: 18086796
references.citation: N Engl J Med. 2010 Nov 4;363(19):1812-21
references.pmid: 21047225
references.citation: Leuk Lymphoma. 2012 Nov;53(11):2283-6
references.pmid: 22424602
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2171-2
references.pmid: 22547611
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2183-9
references.pmid: 22454421
references.citation: Haematologica. 2008 Feb;93(2):257-64
references.pmid: 18223284